- Deep Learning Algorithms have the potential to unlock mechanisms of
tissue regeneration for applications in age-related disease -

June 29, 2016 08:00 AM Eastern Daylight Time

ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE MKT: BTX), a clinical-stage regenerative medicine
company with a focus on pluripotent stem cell technology, today
announced that Co-CEO Dr. Michael D. West, will give a lecture at the
Mensa Annual Gathering today titled, “Hayflick Rewound: Implications of
Reversing the Aging of Human Cells.” Dr. West will discuss the impact of
aging on society, as well as fundamental advances in understanding its
causes and strategies to intervene using regenerative medicine. Dr. West
will describe an online Artificial Intelligence (AI) and Deep Learning
(DL) resource called “Embryonic.AI”
being launched this week by LifeMap Sciences, Inc., a BioTime
subsidiary, for beta testing and designed to discover novel treatments
that cause the body to scarlessly repair tissue damage, an emerging
field called induced Tissue Regeneration (iTR).

The venue of Mensa 2016 was chosen in order to discuss the ongoing
paradigm shift relating to the use of artificially-intelligent systems
to surpass human performance in areas including image recognition,
autonomous driving, and biomedical research. Dr. West's presentation
along with a video describing AI-based discovery and iTR will be
available on BioTime's website in the Events & Presentations section
under Investors & Media.

Mensa, the high IQ society, provides a forum for intellectual exchange
among its members in over 100 countries around the world.

Induced Tissue Regeneration

Humans and most mammals have only a limited capacity to repair tissues
in the body resulting from trauma or degenerative disease. However, some
animals, such as the Mexican salamander can profoundly regenerate
injured tissues, even amputated limbs. Using pluripotent stem cells and
its proprietary PureStem® technology, BioTime
scientists have isolated > 200 diverse embryonic progenitor cell lines
with the potential to regenerate tissue in humans similar to that
occurring in naturally regenerating animals. Key to the uniqueness of
BioTime’s PureStem® technology is the
observation that the cells produced using this proprietary method differ
from adult-derived cells in that they still express molecules associated
with early embryonic development when organs and tissues in the body are
formed for the first time.

The transition from the ability to regenerate tissue in early embryonic
development to the ability to merely produce scar tissue as adults is
one of the most complex processes studied in biology today. BioTime in
collaboration with Insilico
Medicine is investigating the potential ability to apply machine
intelligence to better understand the process. BioTime scientists
believe that leading in this innovative application of AI and
pluripotent stem cell technologies is key to the future of the industry.
Additionally, broader applications of this system could
include personalized regenerative pharmacology, cancer stem cell
research, as well as advances in understanding and intervening in the
aging process. This Computer-based DL program will be available online
at http://discovery.lifemapsc.com
and is called "Embryonic.AI." The discoveries made with Embryonic.AI
have the potential to lead to the ability to induce scarless tissue
regeneration in humans, an emerging field called iTR.

About BioTime

BioTime, Inc. is a clinical-stage biotechnology company focused on
developing and commercializing novel therapies developed from what we
believe to be the world’s premier collection of pluripotent cell assets.
The foundation of our core therapeutic technology platform is
pluripotent cells that are capable of becoming any of the cell types in
the human body. Pluripotent cells have potential application in many
areas of medicine with large unmet patient needs, including various
age-related degenerative diseases and degenerative conditions for which
there presently are no cures. Unlike pharmaceuticals that require a
molecular target, therapeutic strategies based on the use of pluripotent
cells are generally aimed at regenerating or replacing affected cells
and tissues, and therefore may have broader applicability than
pharmaceutical products.

In addition to the development of therapeutics, BioTime’s research and
other activities have resulted, over time, in the creation of other
subsidiaries that address other non-therapeutic market opportunities
such as cancer diagnostics, drug development and cell research products,
and mobile health software applications.

About Insilico Medicine, Inc.

Insilico Medicine, Inc. is a bioinformatics company located at the
Emerging Technology Centers at the Johns Hopkins University Eastern
campus in Baltimore. It utilizes advances in genomics, big data analysis
and deep learning for in silico drug discovery and drug repurposing for
aging and age-related diseases. The company pursues internal drug
discovery programs in cancer, Parkinson's, Alzheimer's, sarcopenia and
geroprotector discovery and provides services to pharmaceutical
companies. Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8

Statements pertaining to future financial and/or operating results,
future growth in research, technology, clinical development, and
potential opportunities for BioTime and its subsidiaries, along with
other statements about the future expectations, beliefs, goals, plans,
or prospects expressed by management constitute forward-looking
statements. Any statements that are not historical fact (including, but
not limited to statements that contain words such as “will,” “believes,”
“plans,” “anticipates,” “expects,” “estimates”) should also be
considered to be forward-looking statements. Forward-looking statements
involve risks and uncertainties, including, without limitation, risks
inherent in the development and/or commercialization of potential
products, uncertainty in the results of clinical trials or regulatory
approvals, need and ability to obtain future capital, and maintenance of
intellectual property rights. Actual results may differ materially from
the results anticipated in these forward-looking statements and as such
should be evaluated together with the many uncertainties that affect the
business of BioTime and its subsidiaries, particularly those mentioned
in the cautionary statements found in BioTime's Securities and Exchange
Commission filings. BioTime disclaims any intent or obligation to update
these forward-looking statements.